Scarica l'app Stockscreener
0.3075
6.40%
0.0185
Dopo l'orario di chiusura:
.31
0.0025
+0.81%
Precedente Chiudi:
$0.289
Aprire:
$0.29
Volume 24 ore:
987.26K
Relative Volume:
1.27
Capitalizzazione di mercato:
$29.22M
Reddito:
$1.22M
Utile/perdita netta:
$-14.15M
Rapporto P/E:
-1.1827
EPS:
-0.26
Flusso di cassa netto:
$-6.55M
1 W Prestazione:
+9.28%
1M Prestazione:
+3.22%
6M Prestazione:
-3.09%
1 anno Prestazione:
-10.87%
Intervallo 1D:
$0.2894
$0.3098
Intervallo di 1 settimana:
$0.276
$0.3098
Portata 52W:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Nome
IGC Pharma Inc
Settore
Industria
Telefono
301-983-0998
Indirizzo
4336 Montgomery Avenue, Bethesda, MD
Confronta IGC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3075 | 27.47M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc Borsa (IGC) Ultime notizie
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsStock Price Forecasts & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (NYSE American: IGC) prices direct 779,997-share stock sale - Stock Titan
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international markets2026 world cup usa national team round of 32 midfield engines high defensive line tactical prediction preview - ulpravda.ru
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (NYSE American: IGC) plans $234K registered stock sale - Stock Titan
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
Small biotech secures cash to keep its Alzheimer's trial moving - Stock Titan
IGC Pharma adjusts fiscal year-end to December 31 - MSN
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates - MSN
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma (IGC) shifts fiscal year-end to December 31 with 9‑month transition - Stock Titan
IGC Pharma, Inc. Approves Change in the Fiscal Year-End from March 31 to December 31 - MarketScreener
IGC Pharma (IGC) Institutional Ownership 2026 - MarketBeat
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc. (IGC) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis
IGC Pharma (FRA:IGS1) EV-to-OCF : -4.65 (As of Dec. 21, 2025) - GuruFocus
How IGC Pharma Inc. stock responds to policy changesWeekly Trend Summary & Long-Term Capital Growth Strategies - Улправда
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Big News Network.com
Will IGC Pharma Inc. stock outperform benchmarksInflation Watch & Verified Swing Trading Watchlists - Улправда
IGC Pharma Secures U.S. Patent for Innovative Stuttering Treatme - GuruFocus
What makes IGC Pharma Inc. stock appealing to growth investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - DonanımHaber
How IGC Pharma Inc. stock benefits from strong dollarWeekly Trade Report & High Return Trade Opportunity Guides - DonanımHaber
Can IGC Pharma Inc. stock deliver strong Q4 earningsWeekly Investment Summary & Technical Buy Zone Confirmation - DonanımHaber
Why IGC Pharma Inc. stock remains stableJuly 2025 Selloffs & Low Risk Growth Stock Ideas - DonanımHaber
Aug Analyst Calls: How IGC Pharma Inc. (IGS1) stock expands through international markets2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
IGC Pharma Inc - Reuters
IGC Pharma comments on potential reclassification of cannabis - MSN
IGC Pharma Increases Authorized Shares to 600 Million - The Globe and Mail
IGC Pharma Positions as a Singular Beneficiary of Emerging Feder - GuruFocus
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Weatherford Democrat
IGC Pharma Inc IGC’s stock price falss traction on Thursday - uspostnews.com
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
IGC Pharma Inc Azioni (IGC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):